International Congress of Drug Therapy in HIV infection (Glasgow 2016), 23-26 October 2016
This year the biennial Glasgow conference was held from 23-26 October 2016.
The meeting has a single-track programme making it easy to attend and follow everything. Important European research is often shown in Glasgow before it is presented at CROI. The Glasgow meeting also supports broad access by webcasting oral presentations.
The programme and abstract book are already online. Webcasts are usually added the day after they were presented.
Published as a supplement to the Journal of the IAS. International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK. JIAS (19) supplement 7 (2016). Online in several formats including PDF and html.
The following reports from this conference are included in this issue of HTB.
- 1000-fold mark-up for drug prices blocks access to HIV, HCV and cancer drugs in high-income countries
- Once-daily raltegravir formulation matches twice-daily results in age, gender, race and baseline viral load/CD4 subgroup analyses
- Attachment inhibitor BMS-068/GSK-934: 96-week results in treatment-experienced patients
- Once-weekly albuvirtide infusion: early results of T-20-like compound
- Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not
- Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients
- Further reports of CNS-related side effects with dolutegravir
- Generic PrEP bought online for UK use is validated by drug testing service
- Immunology and HIV persistence – implications for a cure
- Selected webcasts from Glasgow 2016